Equity Overview
Price & Market Data
Price: $10.75
Daily Change: -$0.815 / 7.58%
Range: $10.41 - $11.20
Market Cap: $737,244,608
Volume: 3,768
Performance Metrics
1 Week: -9.34%
1 Month: 7.18%
3 Months: 21.33%
6 Months: 46.26%
1 Year: 17.49%
YTD: 6.81%
Details
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.